Societal debate on CRISPR should occur: but it won’t…… Of course there is a cost too, but that’s another matter. Lets just see if we can agree that CRISPR is desirable.

Just as politicians and administrators are unable to focus on a meaningful debate about the UKs four health services, they will be unable to debate the ethical challenges, and great opportunities afforded by gene editing. The CRISPR technique holds the potential to reduce greatly many diseases, such as cystic fibrosis and Huntington’s disease. Naturally occurring new mutations will not be preventable, but there is great hope, especially for single gene disorders..

Along with the aforementioned, those who preach about the different faiths will disagree about the best way we can use, control, and benefit from this new technology. Their disagreements, and especially the resistance to change from the right wing fundamentalists, will not advance us. The debate we need on CRISPR will be denied, just as we are denied one on health.

What about the media? Why are they not addressing these issues? It is because they are both complex, and need long words and sentences to describe. They will not sell newsprint or media. The broadsheets may have a go, (it would need to be sustained!) but the Sun and the Mail, main formers of opinion, will duck it. 

In a representative democracy, I have a right to expect my elected MP to be informed and have a view on these matters, but he will not differ from the traditional resistance to change, because he thinks there are more votes to be lost by being in the vanguard of political thinking. One way is for patients with these diseases in their family to demand action from their representatives.

See the source imageOf course there is a cost too, but that’s another matter. Lets just see if we can agree that CRISPR is desirable. Once 95% of the population accept it is more good than bad, what will be our attitude to those who reject it, and incur large expense for the state?

Shaun Griffin in the BMJ July 2th opines: Broad societal debate should inform the use of genome editing in reproduction

Over the last year, I’ve seen many global media stories documenting the incredible technical progress made by researchers using a method of genome editing called CRISPR-Cas9. The purpose is to change the function of a gene—usually from a variant that may cause disease to one that doesn’t. The CRISPR technique, more precise than conventional gene therapy techniques, is already starting to be used therapeutically, and under licence in research using leftover IVF embryos. It also has the potential to be used to alter the DNA of embryos before transfer to the womb, allowing parents to exclude an inherited disease in their future children. Although such “heritable genome editing” is currently illegal in many countries, were that to change, the most likely early application would be for a very few serious inherited genetic conditions, such as cystic fibrosis and Huntington’s disease.

Of course, parents are already making reproductive decisions in the context of expanded opportunities for genetic testing, including preimplantation genetic diagnosis. But, according to a major new report by the Nuffield Council on Bioethics, the ethical considerations of heritable genome editing don’t just impact on parents, but extend far more widely, relating to the interests of their children, wider society, and future generations.

One of the report’s main conclusions is that vastly improved public engagement is essential before any change in policy is made, but also as a condition through which society can express what’s in the public interest. For example, those affected by conditions most tractable to genome editing may have a differing view on its use than the general public; as might those with disabilities, with significant differences of view within these groups.

Given the uncertainly of how safe CRISPR genome editing actually is, with studies, including one this week from the Wellcome Sanger Institute, coming to wildly variable conclusions, the Council report calls for more clinical research on safety before it could be allowed. The Council argues that there is great uncertainty about what heritable editing can actually achieve. For example, we know too little about how genes interact with each other and the environment to have a clue how it could be used in multifactorial disease.

Even if heritable editing using CRISPR were safe for a few conditions with a clear genetic cause, the ethical complexity will increase when its use is considered in human enhancement. That may seem fanciful now, but would enhancements be viewed by society as legitimate if they were for personal gain (e.g. sporting or academic ability in one’s child), or broader social gain (e.g. resistance to epidemics or climate change)? And what impact could this have on groups whose conditions might be edited out? We need to ask such questions of society.

But the importance of proper public engagement extends beyond these wide and complex societal concerns. We know from past experience that well informed public debate, or the lack of it, can make or break the application of a technology. For genetically modified crops, the absence of appropriate engagement, as well as the involvement of big commercial companies, damaged public trust and resulted in a backlash. The progression of GM technology in the UK was effectively stopped in its tracks. Effective debate, on the other hand, can pave the way for progress, as it did for mitochondrial donation, the subject of another Council report. It is now is lawful in the UK. The danger for any new technology is that if perspectives are not shared and misconceptions not addressed, it risks being rejected out of hand.

So far there have been some efforts to engage the public on genome editing, with some useful insights, but it’s fair to say that in the main the “usual suspects” have responded, the engagement has been small scale or not in-depth, and the respondents have not been followed up. This is not a criticism of those who have done so, who include the Council itself, they just haven’t got that role, the resources, or in some cases the neutrality.

The report calls for a new advisory body to be established to lead public debate on genome editing and related areas of scientific and technological development, and to inform Government on policy and governance arrangements. There is a model for public engagement that has positively informed, stimulated and monitored public opinion already. Had it not been edited out of existence in a government cull of quangos in 2012, the Human Genetics Commission would have been an ideal body to do this job. As well preconception genetic testing, the HGC produced reports on genetic profiling of newborns, direct to consumer genetic tests. It also had a panel of people personally affected by genetic conditions to inform its work, as well as working groups on genetic discrimination. It’s time to bring it back.

Shaun Griffin has a PhD in DNA repair from UCL. He has worked in communications and public affairs roles for 20 years at Wellcome, UK Biobank, Human Tissue Authority and the Nuffield Council on Bioethics. He is currently at the Association of Medical Research Charities and is vice chair of a research ethics committee. The article is written in a personal capacity.

Twitter: @drshaungriffin

Declaration of interests: I am a former employee of the Nuffield Council on Bioethics and supported the genome editing project until I left in Jan 2018.

See the source image

 

This entry was posted in A Personal View, Patient representatives, Political Representatives and activists, Professionals, Stories in the Media on by .

About Roger Burns - retired GP

I am a retired GP and medical educator. I have supported patient participation throughout my career, and my practice, St Thomas; Surgery, has had a longstanding and active Patient Participation Group (PPG). I support the idea of Community Health Councils, although I feel they should be funded at arms length from government. I have taught GP trainees for 30 years, and been a Programme Director for GP training in Pembrokeshire 20 years. I served on the Pembrokeshire LHG and LHB for a total of 10 years. I completed an MBA in 1996, and I along with most others, never had an exit interview from any job in the NHS! I completed an MBA in 1996, and was a runner up for the Adam Smith prize for economy and efficiency in government in that year. This was owing to a suggestion (St Thomas' Mutual) that practices had incentives for saving by being allowed to buy rationed out services in the following year.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s